Skip to main content
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. — Investor Relations & Filings

Ticker · APRE ISIN · US03836J1025 US Professional, scientific and technical activities
Open in API
Filings indexed 405 across all filing types
Latest filing 2021-06-10 Regulatory Filings
Country US United States of America
Listing US APRE

About Aprea Therapeutics, Inc.

https://www.aprea.com/

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes novel cancer therapeutics. The company focuses on precision oncology through a synthetic lethality-based approach, targeting DNA Damage Response (DDR) pathways. Its pipeline consists of small molecule therapeutics designed to exploit vulnerabilities associated with cancer cell mutations, aiming to maximize clinical activity and selectivity while minimizing toxicity. Aprea Therapeutics is conducting clinical trials to evaluate its programs in patients with advanced solid tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2021-06-10 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2021, by Aprea Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the first quarter ended March 31, 2021. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length of the document is 3989 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such filings that do not fit other specific categories and are announcements or certifications rather than full reports.
2021-05-06 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about voting on director elections and ratification of the independent auditor, typical content for proxy solicitation materials. The document is titled 'DEFA14A' and references the Annual Meeting to be held on June 9, 2021. It is not the actual annual report or financial statements but materials sent to shareholders to provide information and request votes for the meeting. Therefore, it fits the Proxy Solicitation & Information Statement category (PSI). The document length is 4250 characters, which is consistent with proxy materials rather than a full report.
2021-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-28 English
MS INITIAL
Major Shareholding Notification
2021-03-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.